Veliflapon, formerly known as BAY X 1005 and DG-031, is a leukotriene synthesis inhibitor. BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. BAY-X1005 is a 5-lipoxygenase activating protein (FLAP) inhibitor. BAY-X1005 inhibits the synthesis of leukotrienes B4 and C4 in animal models and it inhibits synthesis of leukotriene B4 in A23187-stimulated leukocytes (IC50 are 0.026, 0.039 and 0.22 μM for rat, mice and human leukocytes respectively) References: Müller-Peddinghaus R. Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005. J Physiol Pharmacol. 1997 Dec;48(4):529-36. Review. PubMed PMID: 9444606.

纯度：≥98%

CAS：128253-31-6